X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/03/25/2851692/29489/en/AIM-ImmunoTech-Announces-Publication-of-Positive-Findings-from-a-Study-Evaluating-Ampligen-in-the-Treatment-of-Pancreatic-Cancer-in-the-Journal-Clinical-Cancer-Research.html
https://www.globenewswire.com//news-release/2024/02/14/2829105/29489/en/AIM-ImmunoTech-Announces-First-Subject-Dosed-in-the-Netherlands-for-Phase-1b-2-Study-Evaluating-Ampligen-rintatolimod-in-Combination-with-AstraZeneca-s-Imfinzi-durvalumab-for-the-T.html
https://www.globenewswire.com//news-release/2024/02/08/2826039/29489/en/AIM-ImmunoTech-Reports-Positive-Topline-Results-from-Phase-2-Study-Evaluating-Ampligen-for-the-Treatment-of-Post-COVID-Conditions.html
https://www.globenewswire.com//news-release/2024/01/22/2813072/29489/en/AIM-ImmunoTech-Announces-that-the-First-Subject-is-Enrolled-in-the-Phase-1b-2-Study-Evaluating-Ampligen-in-Combination-with-AstraZeneca-s-Imfinzi-for-the-Treatment-of-Late-Stage-Pa.html
https://www.globenewswire.com//news-release/2024/01/10/2807133/29489/en/AIM-ImmunoTech-Announces-Open-Enrollment-for-Phase-1b-2-Study-Evaluating-Ampligen-rintatolimod-in-Combination-with-AstraZeneca-s-Imfinzi-durvalumab-for-the-Treatment-of-Pancreatic-.html
https://www.globenewswire.com/news-release/2023/08/08/2720603/29489/en/AIM-ImmunoTech-Announces-Completion-of-Enrollment-in-Phase-2-Study-Evaluating-Ampligen-for-the-Treatment-of-Post-COVID-Conditions.html
https://www.globenewswire.com/news-release/2023/07/10/2701746/29489/en/AIM-ImmunoTech-Enrolls-and-Doses-First-Subject-in-Phase-2-Study-Evaluating-Ampligen-for-the-Treatment-of-Post-COVID-Conditions.html
https://www.globenewswire.com/news-release/2023/06/27/2695563/29489/en/AIM-ImmunoTech-Announces-Publication-of-Positive-Findings-from-a-Pre-Clinical-Study-Evaluating-Ampligen-in-the-Treatment-of-Pancreatic-Cancer-in-the-American-Journal-of-Cancer-Rese.html
https://www.globenewswire.com/news-release/2023/03/08/2623073/29489/en/AIM-ImmunoTech-Announces-Publication-of-New-Analysis-of-the-Mechanism-of-Action-of-Ampligen-as-a-Potential-Prophylactic-Therapy-Against-Ebola-Virus-Disease.html
https://www.globenewswire.com/news-release/2023/02/28/2617118/29489/en/AIM-ImmunoTech-Announces-Phase-2-Study-of-Ampligen-for-the-Treatment-of-Pancreatic-Cancer-is-Open-and-Recruiting-Patients.html
https://www.globenewswire.com/news-release/2023/01/09/2585213/29489/en/AIM-ImmunoTech-Broadens-Patent-Portfolio-with-New-Netherlands-Utility-Patent-Covering-Ampligen-and-Other-AIM-Developed-dsRNA-Products-to-Include-Rugged-dsRNA-for-Use-in-COVID-19-Tr.html
https://www.globenewswire.com//news-release/2022/12/08/2570237/29489/en/AIM-ImmunoTech-Reports-Positive-Safety-Tolerability-and-Biological-Activity-Data-for-Intranasal-Ampligen-Rintatolimod-in-Healthy-Subjects.html
https://www.globenewswire.com/news-release/2022/11/02/2546343/29489/en/AIM-ImmunoTech-Receives-Orphan-Drug-Designation-for-Ampligen-rintatolimod-for-the-Treatment-of-Ebola-Virus-Disease.html
https://www.globenewswire.com/news-release/2022/10/12/2533398/29489/en/AIM-ImmunoTech-Announces-FDA-Clearance-of-IND-Application-to-Evaluate-Ampligen-in-Phase-2-Clinical-Study-for-the-Treatment-of-Post-COVID-Conditions.html
https://www.globenewswire.com/news-release/2022/10/12/2532926/29489/en/AIM-ImmunoTech-Announces-FDA-Clearance-of-IND-Application-to-Evaluate-Ampligen-in-Phase-2-Clinical-Study-for-the-Treatment-of-Post-COVID-Conditions.html
https://www.globenewswire.com/news-release/2022/08/30/2506604/29489/en/AIM-ImmunoTech-and-Study-Collaborator-Roswell-Park-Commence-Enrollment-in-an-NCI-funded-Phase-2-Clinical-Trial-Evaluating-Ampligen-rintatolimod-in-Primary-PD-1-PD-L1-Resistant-Mela.html
https://www.globenewswire.com/news-release/2022/06/13/2461207/29489/en/AIM-ImmunoTech-Bolsters-Intellectual-Property-Portfolio-for-Ampligen-with-Issuance-of-New-Netherlands-Utility-Patent-Covering-Ampligen-and-other-AIM-Developed-dsRNA-Products-for-Us.html
https://www.clinicaltrialsarena.com/news/aim-immunotech-ampligen-covid/
https://www.globenewswire.com/news-release/2021/09/20/2299883/29489/en/AIM-ImmunoTech-Provides-an-Update-on-Its-Pending-Phase-2a-Human-Challenge-Trial-Using-its-Drug-Ampligen.html
https://www.pharmaceutical-technology.com/news/aim-study-ampligen-covid/
https://www.globenewswire.com/news-release/2021/01/29/2166520/0/en/AIM-ImmunoTech-Enters-into-Agreement-for-Proposed-Intranasal-Safety-Study-of-Ampligen.html#:~:text=(NYSE%20American%3A%20AIM)%20today,ongoing%20efforts%20to%20develop%20Ampligen
https://www.clinicaltrialsarena.com/news/company-news/aim-doses-first-patient/
https://www.globenewswire.com/news-release/2020/10/06/2104352/0/en/AIM-ImmunoTech-Announces-IRB-Approval-to-Enroll-COVID-19-Long-Haulers-in-the-AMP-511-ME-CFS-Clinical-Trial-of-Ampligen.html
https://www.proactiveinvestors.com/companies/news/923821/aim-immunotech-inks-pact-with-roswell-park-to-test-ampligen-as-part-of-an-antiviral-treatment-combo-for-covid-19-among-cancer-patients-923821.html
https://www.proactiveinvestors.com/companies/news/921729/aim-immunotech-files-provisional-patent-application-for-ampligen-as-treatment-for-covid-19-induced-fatigue-921729.html
https://aimimmuno.irpass.com/AIM-ImmunoTech-Announces-FDA-Authorization-for-First-Human-Ampligen-Trial-in-COVID-19-Patients-with-Cancer-Provides-Corporate-Business-Update-for-the-First-Quarter-of-2020
https://finance.yahoo.com/news/aim-immunotech-announces-fda-authorization-105000301.html
https://globenewswire.com/news-release/2019/02/15/1726078/0/en/Hemispherx-Biopharma-Announces-Commencement-of-Rights-Offering-Subscription-Period.html
Market Place
Share 
